# US 10,864,182 B2 · Treatment of fragile X syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,182 B2
- Document ID: US10864182B2
- Status: Granted
- Kind: B2
- Application number: 16/383,028
- Filed: 2019-04-12
- Published: 2019-10-17
- Granted: 2020-12-15
- Earliest claimed: 2018-04-13
- Assignees: Healx Limited
- Applicants: Healx Limited
- Inventors: David Brown
- Web page: https://patentgrep.com/patent/US10864182B2

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).

## Claims

### Claim 1

A method of treating fragile x syndrome comprising administering to a subject in need thereof a therapeutically effective amount of sulindac or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 3 (depends on 1)

The method of claim 1, wherein a dose of 50 mg to 400 mg of sulindac is administered.

### Claim 4 (depends on 1)

The method of claim 1, wherein a dose of 50 mg to 300 mg of sulindac is administered.

### Claim 5 (depends on 1)

The method of claim 1, wherein a dose of 150 mg to 200 mg of sulindac is administered.

### Claim 6 (depends on 1)

The method of claim 1, wherein a dose of sulindac is administered once per day.

### Claim 7 (depends on 1)

The method of claim 1, wherein a dose of 300 mg to 400 mg of sulindac is administered once per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein a dose of sulindac is administered twice per day.

### Claim 9 (depends on 1)

The method of claim 1, wherein a dose of 150 mg to 200 mg of sulindac is administered twice per day.

### Claim 10 (depends on 1)

The method of claim 1, wherein sulindac is administered orally.

### Claim 11 (depends on 1)

The method of claim 1, wherein sulindac is administered parenterally, transdermally, sublingually, rectally, or by inhalation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject exhibits signs of hyperactivity, social anxiety, memory loss, or disruptive behaviour.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject exhibits signs of hyperactivity, memory loss, or disruptive behaviour.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is human; and a dose of 300 mg to 400 mg of sulindac is administered once per day.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is human; and a dose of 150 mg to 200 mg of sulindac is administered twice per day.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is human; and a dose of 300 mg to 400 mg of sulindac is administered orally once per day.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject is human; and a dose of 150 mg to 200 mg of sulindac is administered orally twice per day.